

**IN THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) An isolated human antibody or fragment thereof which binds selectively to KDR, comprising complementarity determining regions represented by amino acid sequences selected from the group consisting of:

(a) SEQ ID NO:1 at CDRL1, SEQ ID NO:2 at CDRL2, SEQ ID NO:3 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(b) SEQ ID NO:4 at CDRL1, SEQ ID NO:5 at CDRL2, SEQ ID NO:6 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(c) SEQ ID NO:7 at CDRL1, SEQ ID NO:8 at CDRL2, SEQ ID NO:9 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(d) SEQ ID NO:10 at CDRL1, SEQ ID NO:11 at CDRL2, SEQ ID NO:12 at CDRL3, SEQ ID NO:16 at CDRH1, SEQ ID NO:17 at CDRH2, and SEQ ID NO:18 at CDRH3;

(e) SEQ ID NO:54 at CDRL1, SEQ ID NO:55 at CDRL2, SEQ ID NO:56 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(f) SEQ ID NO:57 at CDRL1, SEQ ID NO:58 at CDRL2, SEQ ID NO:59 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(g) SEQ ID NO:60 at CDRL1, SEQ ID NO:61 at CDRL2, SEQ ID NO:62 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(h) SEQ ID NO:63 at CDRL1, SEQ ID NO:64 at CDRL2, SEQ ID NO:65 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(i) SEQ ID NO:66 at CDRL1, SEQ ID NO:67 at CDRL2, SEQ ID NO:68 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(j) SEQ ID NO:69 at CDRL1, SEQ ID NO:70 at CDRL2, SEQ ID NO:71 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(k) SEQ ID NO:72 at CDRL1, SEQ ID NO:73 at CDRL2, SEQ ID NO:74 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(l) SEQ ID NO:75 at CDRL1, SEQ ID NO:76 at CDRL2, SEQ ID NO:77 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3;

(m) SEQ ID NO:78 at CDRL1, SEQ ID NO:79 at CDRL2, SEQ ID NO:80 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3; and

(n) SEQ ID NO:81 at CDRL1, SEQ ID NO:82 at CDRL2, SEQ ID NO:83 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

2. (original) The antibody of Claim 1, wherein the fragment is selected from the group consisting of a single chain antibody, a Fab, a single chain Fv, a diabody, and a triabody.

3. (original) The antibody of Claim 1, wherein the antibody or fragment thereof inhibits binding of VEGF to KDR.

4. (original) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:1 at CDRL1; SEQ ID NO:2 at CDRL2; SEQ ID NO:3 at CDRL3; SEQ ID NO:13 at CDRH1; SEQ ID NO:14 at CDRH2; and SEQ ID NO:15 at CDRH3.

5. (currently amended) The antibody of Claim 4, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:26 and a heavy chain variable domain represented by SEQ ID NO:24.

6. (original) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:81 at CDRL1; SEQ ID NO:82 at CDRL2; SEQ ID NO:83 at CDRL3; SEQ ID NO:13 at CDRH1; SEQ ID NO:14 at CDRH2; and SEQ ID NO:15 at CDRH3.

7. (currently amended) The antibody of Claim 16, wherein the antibody comprises a light chain variable domain represented ~~respresented~~ by SEQ ID NO:53 and a heavy chain variable domain represented by SEQ ID NO:24.

8. (original) The antibody of Claim 1, wherein the antibody comprises a heavy chain variable domain selected from the group consisting of SEQ ID NO:20, SEQ ID NO:24, and SEQ ID NO:31.

9. (original) The antibody of Claim 1, wherein the antibody comprises a light chain variable domain selected from the group consisting of SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, and SEQ ID NO:53.

10. (original) An isolated polynucleotide which comprises a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, and SEQ ID NO:53.

11. (original) The polynucleotide of Claim 10, wherein the nucleotide sequence is SEQ ID NO:23.

12. (original) The polynucleotide of Claim 10, wherein the nucleotide sequence is SEQ ID NO:25.

13. (original) The polynucleotide of Claim 10, wherein the nucleotide sequence is SEQ ID NO:52.

14. (previously presented) An expression vector comprising the polynucleotide of Claim 10.

15. (original) A recombinant host cell comprising the expression vector of Claim 14.

16. (original) The recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:24 and a polypeptide comprising SEQ ID NO:26.

17. (original) The recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:24 and a polypeptide comprising SEQ ID NO:53.

Claims 18-30 (cancelled)

31. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:4 at CDRL1, SEQ ID NO:5 at CDRL2, SEQ ID NO:6 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

32. (new) The antibody of Claim 31, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:33 and a heavy chain variable domain represented by SEQ ID NO:31.

33. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:7 at CDRL1, SEQ ID NO:8 at CDRL2, SEQ ID NO:9 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

34. (new) The antibody of Claim 33, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:29 and a heavy chain variable domain represented by SEQ ID NO:24.

35. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by

SEQ ID NO:10 at CDRL1, SEQ ID NO:11 at CDRL2, SEQ ID NO:12 at CDRL3, SEQ ID NO:16 at CDRH1, SEQ ID NO:17 at CDRH2, and SEQ ID NO:18 at CDRH3.

36. (new) The antibody of Claim 35, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:22 and a heavy chain variable domain represented by SEQ ID NO:20.

37. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:54 at CDRL1, SEQ ID NO:55 at CDRL2, SEQ ID NO:56 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

38. (new) The antibody of Claim 37, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:35 and a heavy chain variable domain represented by SEQ ID NO:24.

39. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:57 at CDRL1, SEQ ID NO:58 at CDRL2, SEQ ID NO:59 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

40. (new) The antibody of Claim 39, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:37 and a heavy chain variable domain represented by SEQ ID NO:24.

41. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:60 at CDRL1, SEQ ID NO:61 at CDRL2, SEQ ID NO:62 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

42. (new) The antibody of Claim 41, wherein the antibody comprises a light chain variable domain represented by SEQ ID

NO:39 and a heavy chain variable domain represented by SEQ ID NO:24.

43. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:63 at CDRL1, SEQ ID NO:64 at CDRL2, SEQ ID NO:65 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

44. (new) The antibody of Claim 43, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:41 and a heavy chain variable domain represented by SEQ ID NO:24.

45. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:66 at CDRL1, SEQ ID NO:67 at CDRL2, SEQ ID NO:68 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

46. (new) The antibody of Claim 45, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:43 and a heavy chain variable domain represented by SEQ ID NO:24.

47. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:69 at CDRL1, SEQ ID NO:70 at CDRL2, SEQ ID NO:71 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

48. (new) The antibody of Claim 47, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:45 and a heavy chain variable domain represented by SEQ ID NO:24.

49. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:72 at CDRL1, SEQ ID NO:73 at CDRL2, SEQ ID NO:74 at

CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

50. (new) The antibody of Claim 49, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:47 and a heavy chain variable domain represented by SEQ ID NO:24.

51. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:75 at CDRL1, SEQ ID NO:76 at CDRL2, SEQ ID NO:77 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

52. (new) The antibody of Claim 51, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:49 and a heavy chain variable domain represented by SEQ ID NO:24.

53. (new) The antibody of Claim 1, wherein the antibody comprises complementarity determining regions represented by SEQ ID NO:78 at CDRL1, SEQ ID NO:79 at CDRL2, SEQ ID NO:80 at CDRL3, SEQ ID NO:13 at CDRH1, SEQ ID NO:14 at CDRH2, and SEQ ID NO:15 at CDRH3.

54. (new) The antibody of Claim 53, wherein the antibody comprises a light chain variable domain represented by SEQ ID NO:51 and a heavy chain variable domain represented by SEQ ID NO:24.

55. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:31 and a polypeptide comprising SEQ ID NO:33.

56. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:29 and a polypeptide comprising SEQ ID NO:24.

57. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:20 and a polypeptide comprising SEQ ID NO:22.

58. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:35 and a polypeptide comprising SEQ ID NO:24.

59. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:37 and a polypeptide comprising SEQ ID NO:24.

60. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:39 and a polypeptide comprising SEQ ID NO:24.

61. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:41 and a polypeptide comprising SEQ ID NO:24.

62. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:43 and a polypeptide comprising SEQ ID NO:24.

63. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:45 and a polypeptide comprising SEQ ID NO:24.

64. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:47 and a polypeptide comprising SEQ ID NO:24.

65. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:49 and a polypeptide comprising SEQ ID NO:24.

66. (new) A recombinant host cell of Claim 15 which produces a polypeptide comprising SEQ ID NO:51 and a polypeptide comprising SEQ ID NO:24.